Cost-benefit analysis of calcium and vitamin D supplements
Autor: | Heike A. Bischoff-Ferrari, Connie M. Weaver, Christopher J. Shanahan |
---|---|
Přispěvatelé: | University of Zurich, Weaver, Connie M |
Rok vydání: | 2019 |
Předmět: |
Adult
Male 0301 basic medicine Relative risk reduction 11221 Clinic for Geriatric Medicine Cost-Benefit Analysis Osteoporosis chemistry.chemical_element 610 Medicine & health 030209 endocrinology & metabolism Calcium Cost savings 03 medical and health sciences 2732 Orthopedics and Sports Medicine 0302 clinical medicine Meta-Analysis as Topic Environmental health medicine Vitamin D and neurology Humans media_common.cataloged_instance Orthopedics and Sports Medicine Vitamin D European union health care economics and organizations Aged Randomized Controlled Trials as Topic media_common Cost database Cost–benefit analysis business.industry Middle Aged medicine.disease Calcium Dietary Bone fracture chemistry Dietary Supplements Female Original Article Costs and cost analysis 030101 anatomy & morphology business Osteoporotic Fractures Systematic Reviews as Topic |
Zdroj: | Archives of Osteoporosis |
ISSN: | 1862-3514 1862-3522 |
DOI: | 10.1007/s11657-019-0589-y |
Popis: | Summary If all adults with osteoporosis in the European Union (EU) and United States (US) used calcium and vitamin D supplements, it could prevent more than 500,000 fractures/year in the EU and more than 300,000/year in the US and save approximately €5.7 billion and US $3.3 billion annually. Purpose Evaluate the cost-effectiveness of calcium/vitamin D supplementation for preventing osteoporotic fractures. Methods A cost-benefit analysis tool was used to estimate the net cost savings from reduced fracture-related hospital expenses if adults with osteoporosis in the EU and US used calcium/vitamin D supplements. A 14% relative risk reduction of fracture with calcium/vitamin D supplementation from a recent systematic review and meta-analysis of randomized, controlled trials was used as the basis for the benefit estimate. Other model inputs were informed by epidemiologic, clinical, and cost data (2016–2017) obtained via the medical literature or public databases. Analyses estimated the total number of avoided fractures and associated cost savings with supplement use. Net cost benefit was calculated by subtracting the supplements’ market costs from those savings. Results The > 30 million persons in the EU and nearly 11 million in US with osteoporosis experience about 3.9 million and 2.3 million fractures/year and have annual hospital costs exceeding €50 billion and $28 billion. If all persons with osteoporosis used calcium and vitamin D supplements, there would be an estimated 544,687 fewer fractures/year in the EU and 323,566 fewer in the US, saving over €6.9 billion and $3.9 billion; the net cost benefit would be €5,710,277,330 and $3,312,236,252, respectively. Conclusions Calcium and vitamin D supplements are highly cost-effective, and expanded use could considerably reduce fractures and related costs. Although these analyses included individuals aged ≥ 50 years, the observed effects are likely driven by benefits observed in those aged ≥ 65 years. Electronic supplementary material The online version of this article (10.1007/s11657-019-0589-y) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: |